Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xspray Pharma AB ( (SE:XSPRAY) ) has provided an update.
Xspray Pharma AB announced that its rights issue was oversubscribed, leading to an increase and full utilization of the over-allotment issue, raising approximately SEK 161 million before transaction costs. This financial boost is set to strengthen Xspray’s market position, enabling the launch of Dasynoc® upon FDA approval and accelerating development of other products, thereby enhancing its project portfolio and financial resilience.
More about Xspray Pharma AB
Xspray Pharma AB is a pharmaceutical company specializing in developing improved versions of already approved drugs, focusing on oncology treatments. The company leverages its proprietary HyNap technology to enhance drug formulations, aiming to improve patient outcomes and expand market opportunities.
Average Trading Volume: 54,153
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.98B
Learn more about XSPRAY stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test
- “Direct Result of Your Feedback….” Microsoft Stock (NASDAQ:MSFT) Slips as The Option to Skip Updates Emerges